Targeting PIM kinase activity significantly augments the efficacy of cytarabine

British Journal of Haematology

Volumn 156, Issue 1, 2012, Pages 129-132

  Kelly, Kevin R ^a   Espitia, Claudia M ^a   Taverna, Pietro ^b   Choy, Gavin ^b   Padmanabhan, Swaminathan ^a   Nawrocki, Steffan T ^a   Giles, Francis J ^a   Carew, Jennifer S ^a  

^a CTRC Institute for Drug Development   (United States)

^b SuperGen Inc   (United States)

Author keywords

AML; Drug resistance; Leukaemia therapy; New drug development; New drugs for leukaemia

Indexed keywords

CYTARABINE; PROTEIN KINASE PIM 1; PROTEIN KINASE PIM 2; PROTEIN KINASE PIM 3; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE INHIBITOR; SGI 1776; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HUMAN; LETTER; LEUKEMIA CELL LINE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYTARABINE; DRUG SYNERGISM; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; PYRIDAZINES;

EID: 83555166222     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08792.x     Document Type: Letter

References (10)

1. Amaravadi, R. & Thompson, C.B. (2005) The survival kinases Akt and Pim as potential pharmacological targets. Journal of Clinical Investigation, 115, 2618-2624.
2. Carew, J.S., Nawrocki, S.T., Kahue, C.N., Zhang, H., Yang, C., Chung, L., Houghton, J.A., Huang, P., Giles, F.J. & Cleveland, J.L. (2007) Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood, 110, 313-322.
3. Carew, J.S., Nawrocki, S.T., Reddy, V.K., Bush, D., Rehg, J.E., Goodwin, A., Houghton, J.A., Casero, R.A. Jr, Marton, L.J. & Cleveland, J.L. (2008) The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib. Cancer Research, 68, 4783-4790.
4. Chen, L.S., Redkar, S., Bearss, D., Wierda, W.G. & Gandhi, V. (2009) Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 114, 4150-4157.
5. Giles, F. (2005) A Pim kinase inhibitor, please. Blood, 105, 4158-4159.
6. Mumenthaler, S.M., Ng, P.Y., Hodge, A., Bearss, D., Berk, G., Kanekal, S., Redkar, S., Taverna, P., Agus, D.B. & Jain, A. (2009) Pharmacologic inhibition of Pim kinases alters prostate cancer cell growth and resensitizes chemoresistant cells to taxanes. Molecular Cancer Therapeutics, 8, 2882-2893.
7. Nawijn, M.C., Alendar, A. & Berns, A. (2011) For better or for worse: the role of Pim oncogenes in tumorigenesis. Nature Reviews Cancer, 11, 23-34.
8. Swords, R.T., Kelly, K.R., Smith, P.G., Garnsey, J.J., Mahalingam, D., Medina, E., Oberheu, K., Padmanabhan, S., O'Dwyer, M., Nawrocki, S.T., Giles, F.J. & Carew, J.S. (2010) Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood, 115, 3796-3800.
9. Xie, Y., Xu, K., Dai, B., Guo, Z., Jiang, T., Chen, H. & Qiu, Y. (2006) The 44kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene, 25, 70-78.
10. Xie, Y., Burcu, M., Linn, D.E., Qiu, Y. & Baer, M.R. (2010) Pim-1 kinase protects P-glycoprotein from degradation and enables its glycosylation and cell surface expression. Molecular Pharmacology, 78, 310-318.